> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# Empower CEO argues unaffordable medicines should count as a drug shortage
- URL: https://www.healthdatacon.io/articles/empower-noorian-compounding-affordability-drug-shortage/
- Published: 2026-11-17T18:30:00.000Z
- Updated: 2026-11-19T08:28:05.000Z
- Description: Shaun Noorian made the case for patient-specific compounding while calling for clearer distinctions between regulated pharmacies and unlicensed sellers.
- Author: HDM Staff
- Tags: Policy, Americas, HLTH

Empower Pharmacy founder and CEO Shaun Noorian argued that a medicine patients cannot afford should be treated as being in shortage, widening the circumstances in which compounders could help supply it. His November 17 presentation put a commercial and policy argument about access alongside a broader case for adjusting medicines to individual patients’ tolerances, dosage needs and ability to take them.

“I make the argument that if a patient can't get access to a drug due to cost, that drug is in shortage,” Noorian said. That was his proposed standard, not an announcement of a new FDA shortage determination. Empower operates in the compounding business and would have a direct commercial interest in broader access to that market.

Noorian was the sole listed speaker for [The Myth of the Average Patient](https://hlth.com/events/usa/agenda/2026/the-myth-of-the-average-patient?ref=healthdatacon.io), a Pharma Force Stage keynote. His central contention was that population-level evidence remains necessary, while a standard product or dose will not meet every patient’s clinical circumstances.

## Personalization begins with the person taking the medicine

Noorian described compounding as a relationship among the patient, prescriber and pharmacist, contrasting it with the scale and standardized doses of industrial drug manufacturing. He argued that the two approaches answer different needs. A standardized medicine can be supported by population-level evidence while still being unsuitable for a particular person’s formulation or administration requirements.

“Variation is not a failure of medicine. It is biology,” he said. His examples included patients sensitive to an ingredient, people who cannot swallow a capsule and people who struggle with injections. The practical question was whether changing the strength, inactive ingredient or dosage form could make a prescribed treatment more usable for that individual.

He kept the prescribing clinician at the center of those choices. A patient’s preference can help identify a problem with taking a medicine, but the proposed response still needs a clinical rationale. Noorian described the pharmacist working with the prescriber to make that adjustment, rather than patients designing combinations for themselves.

He used his own experience with testosterone treatment to describe how administration discomfort and time spent obtaining an injection affected adherence. He also discussed hormone therapy, hair-loss preparations and GLP-1 medicines as areas where patients and clinicians seek different formulations. Those examples were arguments for individualized prescribing, not comparative clinical evidence establishing that every compounded variation is safer or more effective.

The FDA’s [compounding explanation](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers?ref=healthdatacon.io) recognizes a role when an approved product cannot meet a patient’s medical need, such as an allergy to a dye or difficulty swallowing a solid dosage form. It also distinguishes compounded products from approved generics. A compound is not FDA-approved, and the agency does not review its safety, effectiveness and quality before marketing in the way it reviews an approved drug.

## Affordability and a statutory shortage are different questions

Noorian’s access argument was particularly pointed around GLP-1 medicines. He described patients encountering cost and availability barriers and argued that inability to pay can have the same practical consequence as a backorder: the person does not receive the medicine. From that patient-centered perspective, he urged a broader conception of shortage.

The regulatory position is narrower than that argument. FDA’s [compounder policy update](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize?ref=healthdatacon.io) says semaglutide and tirzepatide are not on its shortage list or the 503B bulks list. It also describes restrictions on regularly making essentially copies of commercially available products under section 503A, and conditions for outsourcing facilities to compound using bulk ingredients under section 503B.

Noorian was therefore asking for a change in how access is treated, rather than describing a general affordability exemption already available to compounders. An individual clinical need, a national shortage determination and a patient’s inability to afford a branded medicine are distinct issues. The keynote did not announce an agency decision changing those boundaries.

He also argued that smaller dosage adjustments or altered formulations could help clinicians address tolerability. The presentation supplied no controlled comparison showing the outcomes of those particular compounded GLP-1 approaches. A claim about a formulation’s flexibility is different from evidence that a specific alternative produces a better clinical result.

## Quality depends on who makes the product and under what conditions

Noorian repeatedly separated licensed compounding from unregulated sellers marketing substances online. He said clinicians and other organizations should ask why the product was prescribed, whether it fits the patient, who produced it and which oversight and quality systems apply. Those questions give a buyer more to assess than the label personalized medicine alone.

He described Empower’s accreditations and manufacturing controls, including testing ingredients, intermediate processes and finished dosage forms. Those were his descriptions of the company’s systems. Facility registration, accreditation and manufacturing standards address important aspects of production, while remaining different from an FDA finding that an individual compounded treatment is safe and effective for a particular use.

The distinction between pharmacy types also matters. FDA describes state-licensed pharmacies and registered outsourcing facilities as operating under different statutory frameworks, with different oversight and manufacturing requirements. Treating them as a single interchangeable category can obscure what an organization is actually purchasing and which quality obligations apply.

## Peptide policy is limited enforcement discretion, not approval

Noorian pointed to the recent HHS peptide policy as another reason the personalization debate is changing. He emphasized ingredient sourcing, single-ingredient formulations and reporting obligations, contrasting those conditions with the uncertain contents of products bought through unregulated channels. His argument was that a controlled supply route can offer more accountability than an informal market.

The [HHS interim policy](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf?ref=healthdatacon.io) concerns section 503A compounding with six specified peptides while rulemaking proceeds. Its conditions include patient-specific prescriptions, qualifying ingredient sources and certificates, product and serious-adverse-event reporting, and limits on formulations and routes. It does not convert those compounded products into FDA-approved drugs or give blanket permission to every seller or outsourcing facility.

That boundary is central to evaluating the presentation. A decision about enforcement while a rule is developed answers a different question from a completed drug approval. Noorian’s call for clearer separation from unlicensed sources does not remove the need to assess the evidence, clinical rationale and quality of each proposed treatment.

“Medicine should be more personalized and never less accountable,” Noorian said in closing. His most significant policy request was to make affordability part of the shortage conversation, while his operational challenge was to explain what distinguishes legitimate patient-specific compounding. The two will require different evidence: a policy case for changing access rules, and a documented clinical and quality case for the medicine an individual patient receives.